This research service presents a marketed and pipeline analysis of the U.S.
type 2 diabetes mellitus market. According to the 2011 National Diabetes Fact
Sheet, 25.8 million children and adults (or 8.3 percent of the population) in
the United States suffer from diabetes. Type 2 diabetes mellitus is the most
common form of diabetes; approximately 90 to 95 percent of diabetes patients
suffer from type 2 diabetes mellitus. The purpose of this study is to
highlight the current market landscape, and provide a competitive analysis of
all marketed and pipeline drugs in development for type 2 diabetes mellitus.
Dashboard slides are provided for all marketed and Phase 3 drugs in
development for type 2 diabetes mellitus.
Table of Contents
Table of Contents
1. Executive Summary
2. Introduction
Market Overview - Segmentation
3. Competitive Landscape
Type 2 Diabetes Competitive Landscape - Orals
Type 2 Diabetes Competitive Lanscape - Parenterals
Product Analysis - Orals
Product Analysis - Parenterals
4. Orals - Meglitinides
Overview
Pipeline Analysis
Product Dashboards
5. Orals - Sulfonylureas
Overview
Product Analysis
Product Dashboards
6. Orals - DPP-4 Inhibitors
Overview
Product Analysis
Pipeline Analysis
Product Dashboards
7. Orals - Biguanides
Overview
Product Analysis
Product Dashboards
8. Orals - Thiasolidinediones
Overview
Product Analysis
Product Dashboards
9. Orals - Alpha-glucosidase Inhibitors
Overview
Product Analysis
Product Dashboards
10. Orals - SGLT2 Inhibitors
Overview
Pipeline Analysis
Detailed Findings
Product Dashboards
11. Orals - Other Orals
Pipeline Analysis
Product Dashboards
12. Parenterals - Incretin Mimetics
Overview
Product and Pipeline Analysis
Product Dashboards
13. Parenterals - Amylin Mimetics
Overview
Product Analysis
Product Dashboard
14. Parenterals - Insulin
Product and Pipeline Analysis
15. Parenterals - Other Parenterals
Pipeline Analysis
16. The Frost & Sullivan Story
A Product and Pipeline Analysis of the U.S. Type 2 Diabetes Mellitus Market published by Frost & Sullivan in February 28, 2012. This report consists of 93 slides and the price starts from US $ 3995.
